• Explore /
  • Poster
  • / Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.

Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.

Abstract Poster

Authors

null

Vera Gorbunova

N. N. Blokhin Cancer Research Center, Moscow, Russian Federation

Vera Gorbunova , Thaddeus Beck , Ralf Hofheinz , Pilar Garcia-Alfonso , Marina Nechaeva , Antonio Cubillo Gracian , Laszlo Mangel , Elena Elez , Dustin A. Deming , Ramesh K. Ramanathan , Alison Torres , Danielle Marie Sullivan , Philip B. Komarnitsky , Jordan Berlin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT02305758

Citation

J Clin Oncol 36, 2018 (suppl; abstr 3543)

DOI

10.1200/JCO.2018.36.15_suppl.3543

Abstract #

3543

Poster Bd #

36

Abstract Disclosures

Similar Posters

First Author: Sotaro Sadahiro

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg

First Author: Bert H. O'Neil